In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ABK Biomedical raises $30mm in Series B round

Executive Summary

ABK Biomedical Inc. (developing microspheres for embolization procedures) raised $30mm through its Series B round co-led by F-Prime and Varian Medical Systems. The company will put the proceeds towards continued development of the Easi-Vue microspheres for treatment of hypervascular tumors and the Eye90 radio-opaque yttrium-90 microspheres for transarterial radiation of liver tumors. First-in-human use of Eye90 is expected in 2020, while the Easi-Vue could be in human studies later this year.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies